Detailed Narrative
Robust Q2 FY26 Financial Performance
India Glycols reported strong financial results for Q2 FY26, with gross revenues increasing 13% year-on-year to INR 2,412 crores. Net revenue also saw a significant rise of 14% to INR 1,092 crores. Profitability metrics showed even greater improvement, with EBITDA growing 33% to INR 160 crores, and EBITDA margins expanding from 12.4% to 14.6%. Net profit (PAT) increased 31% to INR 65 crores, pushing the PAT margin from 5.1% to 5.9%.
Segmental Growth Led by Biofuels and Potable Spirits
The Biofuels segment was a key growth driver, with sales soaring 63% to INR 423 crores for the quarter, and EBIT margins improving from 5.1% to 6.9%. The Potable Spirits business also performed strongly, registering a 24.5% increase in sales to INR 338 crores, with EBIT margins rising from 20.5% to 21.4%. In contrast, the Chemicals business experienced a weak quarter, with sales at INR 288 crores, though EBIT margins expanded from 8.1% to 10.9% due to product mix optimization. Ennature Biopharma contributed INR 43 crores in revenue.
Strategic Debt Reduction and Interest Cost Savings
The company is actively pursuing debt reduction, with plans to utilize INR 467 crores from a preferential allotment along with INR 180 crores from normal repayments, totaling approximately INR 640 crores. This initiative is projected to reduce annual interest costs by INR 60-70 crores starting from the next financial year, enhancing the company's financial efficiency and potentially improving its credit rating.
Biofuels Program and Future Expansion
India Glycols continues to be a significant contributor to the national biofuels program, having supplied 15 crore liters in FY24-25. The company expects to align with the government's target of 20% ethanol blending for FY26. Beyond 2026, the government is exploring an increase to 27% blending, indicating a sustained long-term commitment to the sector, which benefits rural economy, saves forex, and promotes energy independence.
Chemicals Business Focus on High-Value Performance Products
Despite a challenging quarter for overall chemical sales, the segment's margin improvement was attributed to a strategic shift towards new performance chemicals and discontinuing lower-margin businesses. Management expressed confidence in a strong pipeline for performance chemicals, expecting a doubling of revenue and contribution in H2 FY26, with a potential for 10x growth in this segment over the next few years through partnerships with major players like BASF and Dow.
Potable Spirits Market Expansion and Premiumization Strategy
The Potable Spirits business is expanding its market reach, particularly in Kerala, where seven brands, including rum and brandy, have been approved and are expected to drive future growth. The partnership with Amrut for non-malt whisky brands is contributing to premiumization and margin expansion, leveraging Amrut's established name without significant advertising expenditure. The company aims for gradual, consistent growth in premium brands and market share.
Ennature Biopharma Navigates Challenges with Future Optimism
The Ennature Biopharma segment faced pressures from competition in nicotine sales and supply chain disruptions for Thiocolchicoside due to international trade issues and seed shortages. However, the company anticipates a significant improvement in Q4 FY26, following US FDA approval for its plant and ongoing efforts to secure certifications for branded nutraceuticals. The strategy focuses on differentiation through standards, registrations in developing markets, and building a branded portfolio, targeting 40-50% margins for branded nutraceuticals.